MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592499 | Name: Aldioxa

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aldioxa is an Gastrointestinal Agent.

Chemical Structure

Aldioxa
Aldioxa
CAS#5579-81-7

Theoretical Analysis

MedKoo Cat#: 592499

Name: Aldioxa

CAS#: 5579-81-7

Chemical Formula: C4H7AlN4O5

Exact Mass: 218.0232

Molecular Weight: 218.10

Elemental Analysis: C, 22.03; H, 3.24; Al, 12.37; N, 25.69; O, 36.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
RC 172; RC-172; Aldioxa
IUPAC/Chemical Name
Aluminum, ((2,5-dioxo-4-imidazolidinyl)ureato)dihydroxy-
InChi Key
JBSKYLXIYKLOLP-IXYISNAMSA-K
InChi Code
InChI=1S/C4H6N4O3.Al.2H2O/c5-3(10)6-1-2(9)8-4(11)7-1;;;/h1H,(H3,5,6,10)(H2,7,8,9,11);;2*1H2/q;+3;;/p-3/t1-;;;/m1.../s1
SMILES Code
O[Al](OC(N1)=N[C@@H](NC(N)=O)C1=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 218.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Asano T, Aida S, Suemasu S, Tahara K, Tanaka K, Mizushima T. Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia. Sci Rep. 2015 Dec 1;5:17519. doi: 10.1038/srep17519. PubMed PMID: 26620883; PubMed Central PMCID: PMC4664916. 2: Llena C, Forner L, Vento C. Anticalculus efficacy of a new dentifrice. Quintessence Int. 2009 Jun;40(6):497-501. PubMed PMID: 19587891. 3: Guillard O, Huguet F, Fauconneau B, Piriou A, Pineau A. Absence of gastrointestinal absorption or urinary excretion of aluminium from an allantoinate complex contained in two antacid formulations in patients with normal renal function. Eur J Clin Chem Clin Biochem. 1996 Aug;34(8):609-12. PubMed PMID: 8877335. 4: Uchida M, Hamura H, Takagi S, Noguchi Y, Shibata H, Honda H. [Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions]. Nihon Yakurigaku Zasshi. 1994 Mar;103(3):111-20. Japanese. PubMed PMID: 8144103. 5: Kanagawa S, Yosikawa Y, Dohi Y. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure]. Nihon Rinsho. 1991 Dec;49 Suppl:770-4. Japanese. PubMed PMID: 1808348. 6: Ohbayashi S, Misaki N, Bando K, Uchida M, Kawano S. [The effect of aldioxa on the formation of gastritis induced with sodium hydroxide]. Nihon Yakurigaku Zasshi. 1990 Nov;96(5):255-63. Japanese. PubMed PMID: 2279713. 7: Uchida M, Nishimura N, Misaki N, Ikarashi Y, Kobayashi M, Kawano O. [Effect of anti-ulcer drugs and PGE2 on the proliferation of rat gastric cultured cells]. Nihon Yakurigaku Zasshi. 1990 Apr;95(4):185-90. Japanese. PubMed PMID: 2370034. 8: Umemoto M, Nakamura S, Okumura S, Sekiguchi T, Nishihara T, Nishimura T, Hayashi S. [Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats]. Nihon Yakurigaku Zasshi. 1989 Nov;94(5):281-7. Japanese. PubMed PMID: 2613107. 9: Hirota K, Kawase M, Ohmori S. High-performance liquid chromatographic method for the determination of plasma allantoin. J Chromatogr. 1983 Oct 14;277:165-72. PubMed PMID: 6643602. 10: Sato K, Abe H, Nagai M, Ueno M. [Spectrophotometric determination of aldioxa in pharmaceutical preparations]. Yakugaku Zasshi. 1983 Oct;103(10):1100-2. Japanese. PubMed PMID: 6674489. 11: Fukawa K, Misaki N, Kawano O, Uchida M, Ohbayashi S, Irino O. [Experimental studies on gastric ulcer (5). Endoscopical evaluation of healing processes of acetic acid ulcer in rats (1). Ulcer reducing process]. Nihon Yakurigaku Zasshi. 1983 Feb;81(2):167-74. Japanese. PubMed PMID: 6687876. 12: Yamagata S, Miura K. Therapeutic effects of cetraxate against acute gastritis and acute aggravation of chronic gastritis. Endoscopic investigation by the double-blind method. Arzneimittelforschung. 1983;33(8):1191-5. PubMed PMID: 6357203. 13: CAHEN R, PESSONNIER A. [Study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. V. Effect on cicatrization of gastric ulcer]. Ann Pharm Fr. 1963 May;21:405-11. French. PubMed PMID: 14017702. 14: CAHEN R, PESSONNIER A. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. IV. Effect on experimental drug-induced ulcer]. Ann Pharm Fr. 1963 Mar;21:215-22. French. PubMed PMID: 14017701. 15: CAHEN R, PESSONNIER A. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. III. Anti-ulcerous effect]. Ann Pharm Fr. 1962 Sep-Oct;20:704-13. French. PubMed PMID: 14017700. 16: CAHEN R, CLEMENT JF. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. II. Study of the gastric activity]. Ann Pharm Fr. 1962 Sep-Oct;20:693-703. French. PubMed PMID: 14017695. 17: CAHEN R, PESSONNIER A. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity]. Ann Pharm Fr. 1962 Jul-Aug;20:623-36. French. PubMed PMID: 14017699.